Views Among the General Public on New Anti-Obesity Medications and on the Perception of Obesity as a Failure of Willpower.

IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM
Obesity Science & Practice Pub Date : 2025-04-22 eCollection Date: 2025-04-01 DOI:10.1002/osp4.70041
Maya Goldkorn, Barry Schwartz, John Monterosso
{"title":"Views Among the General Public on New Anti-Obesity Medications and on the Perception of Obesity as a Failure of Willpower.","authors":"Maya Goldkorn, Barry Schwartz, John Monterosso","doi":"10.1002/osp4.70041","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The experience of obesity stigma is associated with negative clinical outcomes that include increased mental health problems and additional weight gain. Researchers have treated the public view that obesity is caused by poor willpower as both an <i>element</i> of obesity stigma and as a <i>cause</i> of obesity stigma. Here we test the hypothesis that awareness of new and effective glucagon-like peptide receptor agonist anti-obesity medications (AOMs) will encourage the view that obesity is a biologically-determined medical condition rather than a personal willpower failure and thereby lessen obesity stigma.</p><p><strong>Materials and methods: </strong>Two questionnaire studies, in which participants were randomly assigned to either read about the success of AOMs or to read various alternative material (<i>N</i> = 640 in total), investigated the effect that AOM awareness has on views of obesity.</p><p><strong>Results: </strong>Contrary to the study hypotheses, reading about AOMs did not increase the degree to which participants viewed obesity as a medical condition, nor did it reduce the role willpower failure was believed to play in obesity. Across conditions, participants reporting more personal success in weight loss without medication indicated greater belief that obesity was amenable to self-control, expressed greater obesity stigma, and held less positive attitudes toward the use of AOMs to manage weight.</p><p><strong>Conclusion: </strong>Taken together, these two studies provide no evidence that the success of AOMs will, in the short-term, lead to changes in how people view the etiology of obesity or to a reduction in obesity stigma. Correlational data suggest the possibility that blame and stigma associated with obesity may be robustly informed by participants' understanding of their own experiences managing weight.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"11 2","pages":"e70041"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012989/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Science & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/osp4.70041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The experience of obesity stigma is associated with negative clinical outcomes that include increased mental health problems and additional weight gain. Researchers have treated the public view that obesity is caused by poor willpower as both an element of obesity stigma and as a cause of obesity stigma. Here we test the hypothesis that awareness of new and effective glucagon-like peptide receptor agonist anti-obesity medications (AOMs) will encourage the view that obesity is a biologically-determined medical condition rather than a personal willpower failure and thereby lessen obesity stigma.

Materials and methods: Two questionnaire studies, in which participants were randomly assigned to either read about the success of AOMs or to read various alternative material (N = 640 in total), investigated the effect that AOM awareness has on views of obesity.

Results: Contrary to the study hypotheses, reading about AOMs did not increase the degree to which participants viewed obesity as a medical condition, nor did it reduce the role willpower failure was believed to play in obesity. Across conditions, participants reporting more personal success in weight loss without medication indicated greater belief that obesity was amenable to self-control, expressed greater obesity stigma, and held less positive attitudes toward the use of AOMs to manage weight.

Conclusion: Taken together, these two studies provide no evidence that the success of AOMs will, in the short-term, lead to changes in how people view the etiology of obesity or to a reduction in obesity stigma. Correlational data suggest the possibility that blame and stigma associated with obesity may be robustly informed by participants' understanding of their own experiences managing weight.

公众对新型抗肥胖药物的看法,以及认为肥胖是意志力的失败。
背景:肥胖耻辱感的经历与负面的临床结果相关,包括增加的心理健康问题和额外的体重增加。研究人员认为,公众认为肥胖是由意志力差引起的,这既是肥胖污名的一个因素,也是肥胖污名的一个原因。在这里,我们验证了这样一个假设,即认识到新的和有效的胰高血糖素样肽受体激动剂抗肥胖药物(AOMs)将鼓励人们认为肥胖是一种生物决定的医学状况,而不是个人意志力失败,从而减轻肥胖的污名。材料和方法:两项问卷调查研究,参与者被随机分配阅读关于AOM成功或阅读各种替代材料(N = 640),调查AOM意识对肥胖观点的影响。结果:与研究假设相反,阅读关于AOMs的文章并没有增加参与者将肥胖视为一种医学疾病的程度,也没有减少意志力失败在肥胖中所起的作用。在不同的条件下,报告在没有药物的情况下减肥成功的参与者更相信肥胖是可以自我控制的,表达了更多的肥胖耻辱感,并且对使用AOMs来控制体重的态度不那么积极。结论:综上所述,这两项研究没有提供证据表明,在短期内,AOMs的成功将改变人们对肥胖病因的看法,或减少肥胖的耻辱感。相关数据表明,与肥胖相关的指责和耻辱可能会从参与者对自己管理体重的经历的理解中得到强有力的信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Obesity Science & Practice
Obesity Science & Practice ENDOCRINOLOGY & METABOLISM-
CiteScore
4.20
自引率
4.50%
发文量
73
审稿时长
29 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信